NCT06531447View on ClinicalTrials.gov

First-line Gemcitabine Plus Cisplatin in Locally Advanced (IIIC Stage) Breast Cancer Patients

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

November 30, 2017

Study Completion Date

May 31, 2027

Conditions
Breast Cancer
Interventions
DRUG

Cisplatin

Every 21 days 6 cycles

DRUG

Gemcitabine

Every 21 days (First and 8th days) 6 cycles

DRUG

Doxorubicin

Every 21 days 4 cycles

DRUG

Cyclophosphamide

Every 21 days 4 cycles

DRUG

Paclitaxel

Every 21 days 4 cycles or once a week for 12 weeks

Trial Locations (1)

AZ1011

Elchin Mansurov, Baku

All Listed Sponsors
lead

The National Center of Oncology, Azerbaijan

OTHER_GOV

NCT06531447 - First-line Gemcitabine Plus Cisplatin in Locally Advanced (IIIC Stage) Breast Cancer Patients | Biotech Hunter | Biotech Hunter